Sex Differences and 2‐Year Mortality in Patients With Atrial Fibrillation Diagnosed After Stroke and Known Atrial Fibrillation: A Register‐Based Study in Sweden
Journal of the American Heart Association · 15.04.2025 · 14 (8)
DOI: 10.1161/jaha.124.037608 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 15.04.2025. Verfasst von Ilham Al Khatib und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuroscience and Physiology, Rehabilitation Medicine University of Gothenburg Gothenburg Sweden. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke, Ischemic Stroke. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
The objective of this study was to determine associations between atrial fibrillation diagnosed after stroke (AFDAS) and known atrial fibrillation with 2‐year mortality among men and women. Methods and Results This longitudinal, register‐based study included patients with ischemic stroke admitted to 3 hospitals in Gothenburg, Sweden, between November 1, 2014 and June 30, 2019. The exposures were known atrial fibrillation and AFDAS detected at the stroke units. The outcome was all‐cause mortality 2 years after stroke. Cox‐regression analyses were conducted to assess sex differences in relation to the adjusted mortality risk. Of 5468 patients with ischemic stroke, 2583 (47%) were women, and the mean age was 74 years (SD 14). Overall, 19% had known atrial fibrillation, and 10% had AFDAS. Women were older and had more severe strokes compared with men. Within the first month, women with AFDAS did not have an increased risk of mortality compared with women with no atrial fibrillation (hazard ratio, 0.93 [95% CI, 0.46–1.88]), in contrast to men with AFDAS who had an increased risk (hazard ratio, 2.14 [95% CI, 1.07–4.26]). Men and women with AFDAS had an increased risk of long‐term mortality (31 days to 2 years) compared with those with no atrial fibrillation. Known atrial fibrillation was associated with the highest poststroke mortality irrespective of sex and time interval.
Conclusions
Our findings suggest that underlying sex differences exist in the association between the occurrence of AFDAS and poststroke mortality. Sex differences related to the timing of atrial fibrillation diagnosis should be considered when developing preventive measures and medical care after stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Neuroscience and Physiology, Rehabilitation Medicine University of Gothenburg Gothenburg Sweden.
- Department of Rehabilitation Medicine, Neurocare Sahlgrenska University Hospital Gothenburg Sweden.
- Department of Occupational Therapy and Physiotherapy Sahlgrenska University Hospital Gothenburg Sweden.
ORCID-Profile: Adam Viktorisson, Tamar Abzhandadze, Katharina S Sunnerhagen
Zitieren
APA
Al Khatib, I., Viktorisson, A., Abzhandadze, T., & Sunnerhagen, K. S. (2025). Sex Differences and 2‐Year Mortality in Patients With Atrial Fibrillation Diagnosed After Stroke and Known Atrial Fibrillation: A Register‐Based Study in Sweden. Journal of the American Heart Association, 14(8). https://doi.org/10.1161/jaha.124.037608
Vancouver
Al Khatib I, Viktorisson A, Abzhandadze T, Sunnerhagen KS. Sex Differences and 2‐Year Mortality in Patients With Atrial Fibrillation Diagnosed After Stroke and Known Atrial Fibrillation: A Register‐Based Study in Sweden. Journal of the American Heart Association. 2025;14(8). doi:10.1161/jaha.124.037608
BibTeX
@article{AlKhatib2025,
author = {Al Khatib, Ilham and Viktorisson, Adam and Abzhandadze, Tamar and Sunnerhagen, Katharina S},
title = {Sex Differences and 2‐Year Mortality in Patients With Atrial Fibrillation Diagnosed After Stroke and Known Atrial Fibrillation: A Register‐Based Study in Sweden},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {8},
doi = {10.1161/jaha.124.037608}
}
EUVIMED